TopNews

Technical analyst Hitesh Chotalia has maintained 'buy' rating on Hindalco Industries Limited stock with a target of Rs 240.

According to analyst, the investors can purchase the stock with a stop loss of Rs 225.

The stock of the company, on February 01, closed at Rs 229.85 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 251.90 and a low of Rs 133.10 on BSE.

Current EPS & P/E ratio stood at 10.76 and 21.67 respectively.

Technical analyst Rakesh Bansal of New Age Wealth has maintained 'buy' rating on Infrastructure Development Finance Company Limited (IDFC) stock with a target of Rs 154

According to analyst, the investors can purchase the stock with a stop loss of Rs 139.

The stock of the bank, on February 01, closed at Rs 142.95 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 218.20 and a low of Rs 142 on BSE.

Current EPS & P/E ratio stood at 8.37 and 17.25 respectively.

Mumbai,

Owing to civil unrest in Egypt and signs of slowing economic growth in China, oil dropped from a two-year high in New York.

For a second day, Brent crude traded at more than $100 per barrel and its premium narrowed for a third day to New York crude. This has propelled Chinese investors and traders to sell contracts after the biggest two-day rally since May.

ICE Futures fell by 1.1 percent after officials said traffic is moving normally through the Suez Canal main artery with more than 2.2 million barrels of oil a day.

As per government data released on Tuesday, country’s exports in December succeed over imports for the same month.

There is an increase of 36.4% in exports taking the figure to USD 22.5 billion, whereas imports were recorded at USD 25.1 billion which shows a fall of 11.1% on year-on-year basis.

India's trade deficit in November was recorded at USD 8.9 billion narrowed down in December to USD 2.6 billion. There is an annual rise in April-December exports by 29.5% to USD 164.7 billion.

Glenmark a Pharmaceutical firm posted net profit of Rs 109.55 crore in the quarter ended December 31, 2010 which shows that its net profit rose by 16.45% as compared to same quarter last year.

In a filing to the Bombay Stock Exchange (BSE) Glenmark Pharmaceuticals said that net profit of the company are boosted by the impressive performance of its India formulations business.